Anti-CTLA4 treatment reduces lymphedema risk potentially through a systemic expansion of the FOXP3+ Treg population.
Wolf S, Madanchi M, Turko P, Hollmén M, Tugues S, von Atzigen J, Giovanoli P, Dummer R, Lindenblatt N, Halin C, Detmar M, Levesque M, Gousopoulos E.
Wolf S, et al. Among authors: madanchi m.
Nat Commun. 2024 Dec 30;15(1):10784. doi: 10.1038/s41467-024-55002-6.
Nat Commun. 2024.
PMID: 39737964
Free PMC article.